Story perspectives

Resmed Sees 11% Revenue Surge Amid Sleep Health Expansion

2/11/2025

41 9

Summary

Story summary

Resmed, an Australian biotech, focuses on sleep apnea devices and digital health solutions.
The FDA approved Eli Lilly’s Zepbound for obesity-related sleep apnea, potentially improving CPAP therapy adherence.
Resmed's revenue rose 11% to US$2.5 billion in the last six months, driven by strong device sales.
The company targets expanding its user base from 147 million to 500 million by 2030.
Despite competition, Resmed is optimistic about growth in the sleep health market.

1 of 1

Story summary

Resmed, an Australian biotech, focuses on sleep apnea devices and digital health solutions.
The FDA approved Eli Lilly’s Zepbound for obesity-related sleep apnea, potentially improving CPAP therapy adherence.
Resmed's revenue rose 11% to US$2.5 billion in the last six months, driven by strong device sales.
The company targets expanding its user base from 147 million to 500 million by 2030.
Despite competition, Resmed is optimistic about growth in the sleep health market.